News for Neurocrine Biosciences, Inc. (NBIX)

**media[563711]**

LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. ( VYGR), a biotechnology company dedicated to advancing neurogenetic medicines

- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profil

**media[552837]**

Neurocrine Biosciences Inc (NBIX), a leading neuroscience-focused biopharmaceutical company, announced on February 25, 2025, that it will participate in two sig

LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. ( VYGR), a biotechnology company dedicated to advancing neurogenetic medicines,

Shares of Neurocrine Biosciences Inc (NBIX) surged 3.94% in mid-day trading on Feb 23. The stock reached an intraday high of $122.37, before settling at $120.

On February 21, 2025, Neurocrine Biosciences Inc (NBIX), a leading neuroscience-focused biopharmaceutical company, announced that its Board of Directors has aut

On December 31, 2024, BRAIDWELL LP (Trades, Portfolio) executed a significant transaction involving the acquisition of shares in DBV Technologies SA. The firm a

**media[537489]**

We recently compiled a list of the These 10 Firms Were Last Week's Worst Performers. In this article, we are going to take a look at where Neurocrine Biosciences Inc.

We recently compiled a list of the 10 Companies Echo Friday's Market Pessimism. In this article, we are going to take a look at where Neurocrine Biosciences Inc.

INGREZZA Sales Guidance for 2025: $2.5 billion to $2.6 billion, reflecting $250 million growth at the midpoint.CRENESSITY Q4 2024 Sales: $2 million in net sale

Feb 06, 2025 / 09:30PM GMTOperator Good day, everyone, and welcome to today's Neurocrine Biosciences reports Q4 and fiscal year 2024 Earnings Call. (Operator In

Earnings Call Insights: Neurocrine Biosciences (NASDAQ:NBIX) Q4 2024Management ViewCEO Kyle Gano highlighted Neurocrine's transformation into a fully...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ETCompany ParticipantsTodd Tushla - Vice President of...

Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences Inc (NBIX) released its financial results for the fourth quarter and full year of 2024 on February 6, 2025. The company reported signific

PR NewswireSAN DIEGO, Feb. 6, 2025 INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Represent